To hear about similar clinical trials, please enter your email below
Trial Title:
Delving Into Participation Trends in Renal Cell Carcinoma Studies
NCT ID:
NCT06093568
Condition:
Renal Cell Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Renal Cell
Conditions: Keywords:
Renal Cell Carcinoma
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Summary:
The study seeks to delve into the firsthand experiences of patients diagnosed with renal
cell carcinoma who partake in a separate clinical study featuring a specific medical
intervention. The primary emphasis will be on meticulously tracking the rates of trial
completion and withdrawal among these individuals.
By joining this clinical trial, individuals have the unique opportunity to contribute to
the betterment of future renal cell carcinoma patients and play an active role in
advancing clinical research.
Criteria for eligibility:
Study pop:
People with renal cell carcinoma who are actively considering enrolling in an
observational clinical trial, but have not yet completed enrollment and randomization.
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
- Patient has been diagnosed with renal cell carcinoma
- Patient is a minimum of 18 years or older
- Patient has self-identified as planning to enroll in a clinical study
Exclusion Criteria:
- Patient does not understand, sign, and return consent form
- Inability to perform regular electronic reporting
- Patient is pregnant
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Power Life Sciences
Address:
City:
San Francisco
Zip:
94107
Country:
United States
Contact:
Last name:
Michael B Gill
Phone:
415-900-4227
Email:
https://www.withpower.com/contact-us@withpower.com
Start date:
November 2024
Completion date:
November 2026
Lead sponsor:
Agency:
Power Life Sciences Inc.
Agency class:
Industry
Source:
Power Life Sciences Inc.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06093568
